Comparative Pharmacology
Head-to-head clinical analysis: LOXITANE C versus MELLARIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOXITANE C versus MELLARIL.
LOXITANE C vs MELLARIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loxapine, a dibenzoxazepine antipsychotic, acts primarily by blocking dopamine D2 receptors in the brain. It also exhibits affinity for serotonin 5-HT2A receptors, alpha-adrenergic, histaminergic, and muscarinic receptors, contributing to its antipsychotic and sedative effects.
Thioridazine is a phenothiazine antipsychotic that blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors, and also blocks alpha-adrenergic receptors, histamine H1 receptors, and muscarinic M1 receptors.
10 mg orally twice daily initially; may increase by 10 mg/day every 3–4 days; usual therapeutic range 60–100 mg/day; maximum 250 mg/day.
Typical adult dose: 10-25 mg orally 3 times daily. Maximum dose: 200 mg/day.
None Documented
None Documented
Terminal elimination half-life is 4-8 hours (mean 6 hours). Clinical context: Requires multiple daily dosing; stable plasma levels achieved by second day.
Terminal elimination half-life 21-24 hours; steady-state achieved within 5-7 days
Approximately 70% renal (mainly as conjugated metabolites, <1% unchanged), 30% fecal via biliary excretion.
Primarily renal (70-80% as metabolites, <1% unchanged); biliary/fecal (20-30%)
Category C
Category C
Antipsychotic
Antipsychotic